MOH Holdings Pte Ltd.

The Singaporean Ministry of Health is investing SG$200 million ($150 million) over the next five years to further implement new AI technologies across the island-nation state's health system. This new infusion to the MOH Health Innovation Fund supports the development and testbedding of technological innovations, including AI, making a "centralised push to scale them up into system-wide, national projects," the ministry said in a statement. It includes a generative AI project that automates record updating, which will be rolled out across the public healthcare system before end-2025. The MOH said it is committing to promote the use of genAI tools to "automate repetitive and time-consuming tasks, such as documentation and summarisation of medical records." The ministry will also validate medical imaging AI that assists with breast cancer detection, which is eyed for progressive adoption as part of a national subsidised screening programme from end-2025. THE LARGER TREND There are ongoing government-backed initiatives across the Singaporean health system to build and integrate genAI models and applications. Last year, the national health tech agency Synapxe expanded its partnership with Microsoft to, among other projects, develop the Secure GPT for Healthcare Professionals, a common platform for developing large language models and genAI applications. The National University Health System also developed its own LLM-based chatbot called NUHS RUSSELL-GPT, which can summarise patient case notes and quickly write referral letters. Meanwhile, Singapore General Hospital has also taken an interest in applying genAI as part of pre-surgery assessments. The MOH is also promoting the uptake of medical imaging AI through the national radiology AI platform AimSG . Introduced last year, this vendor-neutral platform allows public hospitals to integrate validated AI into their workflows. Through this, two hospitals under SingHealth have adopted chest X-ray analysis AI. The National Healthcare Group is currently piloting the same AI in its cluster. Alongside announcing new AI investments, the MOH also shared its plan to launch a national genetic testing programme by the middle of next year, initially targeting Familial Hypercholesterolemia. Additionally, the MOH said it will improve the national governance on AI use in healthcare "to enable the development and deployment of more AI solutions while ensuring safe and secure care delivery to patients."

Biofourmis founder launches health LMM startup Over a year after leaving biotechnology unicorn Biofourmis, ex-CEO and founder Kuldeep Singh Rajput recently announced that he set up a new health tech company focused on generative AI. In a LinkedIn post, he shared that his newly founded startup, OutcomesAI, has partnered with SingHealth to deploy its large multi-modal model (LMM) called Glia, which allows organisations to build clinician companion AI. National Heart Centre Singapore and National Cancer Centre Singapore were identified as the first sites of the LMM integration. JLK bags 510(k) for CT perfusion AI South Korean medical AI company JLK has obtained another regulatory approval in the United States for one of its stroke AI offerings. The company received its third 510(k) clearance from the US Food and Drug Administration for JLK-CTP, which uses AI to automatically identify the centre of cerebral infarction and the area of cerebral hypoperfusion in brain CT perfusion images. JLK received its first 510(k) in June for its MRI-based prostate analysis AI software, then a second one for another stroke AI solution that specifically detects large vessel occlusion in brain CT scans. Korea OKs Heuron's Parkinson's disease AI Fellow Korean medical imaging AI company, Heuron, also recently received regulatory approval from the South Korean Ministry of Food and Drug Safety. According to a press statement, its AI-powered software HeuronNM identifies and quantifies neuromelanin – a key biomarker of Parkinson's disease – in brain 3D MRI images. Meanwhile, Heuron is currently working to secure FDA approvals in Thailand for its range of AI solutions following its expansion there in August. Wadhwani AI backs AIIMS Indian non-profit Wadhwani Institute for Artificial Intelligence (Wadhwani AI) has been tapped to support the All India Institute of Medical Sciences in New Delhi in its healthcare AI integration projects. AIIMS was recently designated as one of India's "AI centres of excellence" under the government's Make AI in India, Make AI Work for India initiative, in which healthcare is one of the priority areas. As a partner, Wadhwani AI will be deploying its AI solutions that support the diagnosis of chest conditions and diabetic retinopathy. The Indian government has pledged to invest over $110 million in supporting the AI COEs over the next four years. NUS Medicine establishes digital health accelerator The Yong Loo Lin School of Medicine of the National University of Singapore (NUS Medicine) has recently launched an accelerator programme for digital health startups, including those developing AI solutions in mental health and hospital administration. A collaboration with 22Health Ventures, the Digital Accelerator Programme of the NUS Medicine Digital Advanced Technology Accelerator aims to support startups from conception through global expansion. The cohort includes 2Strands, which develops blood-based cancer recurrence monitoring tests; Health BETA, which offers genetic tests and digital therapeutics for personalised health monitoring; HealthBridge AI, which is currently testing its clinical product for streamlining administrative tasks; Marymount Lab, which provides patient engagement software for preventive health; and TenangAI, which offers an AI-driven solution to support youth mental health.

SINGAPORE, Oct. 14, 2024 /PRNewswire/ -- Vivance, a leader in kidney care innovations, is proud to announce that the next trial phase of the wearable peritoneal dialysis (PD) device, Viva Kompact, has successfully concluded. The study was conducted at Singapore General Hospital (SGH), Singapore. The study data will be shared at American Society of Nephrology (ASN) Kidney Week, happening from 23-27 October 2024 at the San Diego Convention Center. Viva Kompact received US Food and Drug Administration (FDA)'s breakthrough device designation in 2019 following the completion of the First-in-Human clinical trial. Earlier this year, the pre-pivotal trial was completed, focusing on evaluating the device's performance and safety parameters while being independently used by patients in their home environment. "Completing this trial is a momentous achievement for our team, patients and healthcare professionals who are equally passionate about advancing kidney care to the next level," said Suresha Venkataraya, CEO of Vivance. "We are excited to share our findings, which we believe will contribute significantly to advancing the possibility of dialysis anytime, anywhere." The trial results will be presented during oral sessions at Kidney Week by A/Prof. Marjorie Foo, the Principal Investigator and Senior Consultant, Department of Renal Medicine, SGH, who said, "I am excited to share the findings from this first-of-a-kind wearable dialysis device which underwent a trial at Singapore General Hospital. 10 patients were able to independently use the device and successfully complete at least one week of dialysis at their homes, with no device-related serious adverse events." The presentation will provide more information on the performance, efficacy and patient experience of using this wearable device. Mandar Gori, Chief Business Officer of Vivance, who also heads the Clinical Affairs function, said, "We thank all collaborators, especially our clinical advisors, who made the pre-pivotal trial of this FDA-designated breakthrough device possible. We are excited to showcase Viva Kompact along with our other products at booth #829 during the upcoming ASN Kidney Week." Media Contact: Priyanka Arya Senior Marketing Manager +65 6950 5011 [email protected] About Vivance Vivance, formerly AWAK Technologies, is a pioneering, patient-centric medical technology company with a mission to enhance the lives of people with kidney disease and their caregivers by providing solutions to deliver better outcomes and improve their quality of life. Headquartered in Singapore with offices in Los Angeles, United States and Bengaluru, India, the company is dedicated to the research, development and marketing of novel technologies in kidney care. For more information, please visit . SOURCE Vivance Pte Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED